Diligence memo · auto-generated · as of July 2, 2026

VST BIO Corp

VST BIO Corp looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

VST BIO Corp operates in Pharmaceuticals, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

VST BIO Corp has raised $29M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $29M on 2025-11-05.

Most recent recorded round closed around 2025-11-05.

Valuation (modeled)modeled

Provath models VST BIO Corp at approximately $119M (range $61M–$164M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.07× the median modeled value of Series B Pharmaceuticals companies in 2025–2027 (17 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 8 mo ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 73% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 58% of those peers.

Closest niche peers: Phlow Corp., AlphaTON Capital Corp, Triton Therapeutics, Inc., Sensorium Therapeutics, Inc., Belhaven Biopharma Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.